Maturitas最新文献

{"title":"An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause","authors":"Susann Eichler,&nbsp;Mareike Panz,&nbsp;Anastasia Harder,&nbsp;Clarissa Masur,&nbsp;Manuel Häuser,&nbsp;Erik Schulze zur Wiesche","doi":"10.1016/j.maturitas.2024.107978","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107978","url":null,"abstract":"<div><h3>Objectives</h3><p>The efficacy and tolerability of a non-hormonal pessary (that forms an oil-in-water emollient with the vaginal fluid) were assessed for the treatment of symptoms of vaginal dryness associated with menopause.</p></div><div><h3>Study design</h3><p>Seventy-nine postmenopausal women (mean age 60.8 <span><math><mo>±</mo></math></span> 6.5 years) with mild to moderate symptoms of vaginal dryness (including dyspareunia) were enrolled in this open-label, prospective, post-market clinical follow-up trial, conducted in 2022 by one research center in Germany. The investigational pessary was applied for the first 7 days once daily and the subsequent 31 days twice a week, at bedtime. A treatment-free period of 6 days completed the trial.</p></div><div><h3>Main outcome measures</h3><p>During the trial, participants filled out questionnaires that enabled the calculation of a total severity score for subjective symptoms of atrophy-related vaginal dryness and impairment of daily as well as sexual life. Furthermore, vaginal health index and safety were studied.</p></div><div><h3>Results</h3><p>A rapid and significant reduction in the severity scores for symptoms was observed over the 38-day course of treatment and beyond. Quality of life assessed by DIVA (day-to-day impact of vaginal aging) questionnaire, dyspareunia and vaginal health index also clearly improved. The tolerability was mainly rated as “good to very good” by the investigator and 94.9 % of participants. The vast majority were very satisfied with the simple and pleasant handling. No serious adverse events occurred.</p></div><div><h3>Conclusion</h3><p>Overall, the presented data suggest that the investigated non-hormonal pessary is an effective and well tolerated treatment option for vaginal symptoms associated with dryness, thus improving quality of life for women, even those who are sexually active.</p><p>ClinicalTrials.gov identifier <span>NCT05211505</span><svg><path></path></svg>.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224000732/pdfft?md5=7c60a8d1a6557ac967908298e798996b&pid=1-s2.0-S0378512224000732-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of age at menarche, reproductive lifespan and age at menopause with the risk of atrial fibrillation: The HUNT study","authors":"Hikaru Morooka ,&nbsp;Eirin B. Haug ,&nbsp;Vegard Malmo ,&nbsp;Jan Pål Loennechen ,&nbsp;Kenneth J. Mukamal ,&nbsp;Janet Rich-Edwards ,&nbsp;Abhijit Sen ,&nbsp;Imre Janszky ,&nbsp;Julie Horn","doi":"10.1016/j.maturitas.2024.107979","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107979","url":null,"abstract":"<div><h3>Background</h3><p>Age at menarche, reproductive lifespan, and age at menopause are associated with several cardiovascular diseases, but their relationship with atrial fibrillation (AF) is uncertain.</p></div><div><h3>Methods</h3><p>We linked information on all women who participated in the third survey of the population-based, longitudinal HUNT study in Norway with medical records from all local hospitals. A total of 14,632 women aged 60 or more were followed for validated incident AF. We retrieved age at menarche and age at menopause from the HUNT questionnaires. Reproductive lifespan was defined as the difference between age at menarche and age at menopause. We used Cox proportional hazards regression models to assess associations between AF and age at menarche, reproductive lifespan, and age at menopause.</p></div><div><h3>Results</h3><p>During a median follow-up of 8.17 years (136,494 person-years), 1217 (8.3 %) participants developed AF. In multivariable-adjusted analyses, we observed no associations between early or late age at menarche and AF (hazard ratios (HRs): &lt;12 years: 0.85 [95 % confidence interval (CI), 0.65–1.12]; ≥16 years: 0.99 [95 % CI, 0.80–1.24] compared to those who attained menarche at 13–14 years). The HR for a reproductive lifespan shorter than 30 years was 0.91 [95 % CI, 0.72–1.15] compared to 34–37 years. Likewise, there was no clear association between premature or early age at menopause and AF (HRs: &lt;40 years: 1.21 [95 % CI, 0.83–1.75]; 40–44 years: 0.97 [95 % CI, 0.77–1.22] compared to 50–54 years).</p></div><div><h3>Conclusions</h3><p>In this population of women aged 60 years and over, the risk of AF was not associated with age at menarche, reproductive lifespan, or age at menopause.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140320444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate-intensity continuous training and high-intensity interval training modulate the composition of the oral microbiota of elderly adults: Randomized controlled trial","authors":"María Leyre Lavilla-Lerma,&nbsp;Agustín Aibar-Almazán,&nbsp;Antonio Martínez-Amat,&nbsp;José Daniel Jiménez-García,&nbsp;Fidel Hita-Contreras","doi":"10.1016/j.maturitas.2024.107973","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107973","url":null,"abstract":"<div><h3>Objective</h3><p>We investigates the effects of 16-week high-intensity interval training and moderate-intensity continuous training on the composition of the oral microbiota. To the best of our knowledge, at the time of writing this paper no other scholars had described the oral metagenomic changes associated with prescribed exercise in older adults.</p></div><div><h3>Methods</h3><p>Forty-three participants aged 60–74 years were randomized 1:1:1 to a control group, high-intensity interval training or moderate-intensity continuous training twice weekly for 16 weeks. Saliva samples were sequenced at baseline, week 8 and week 16 of intervention.</p></div><div><h3>Results</h3><p>High-intensity interval training produced significant differences over time in Richness and a clear trend to decreased Simpson and Shannon diversity indices. In contrast, Simpson and Shannon indices showed an upward trend over time with moderate-intensity continuous training, which also decreased <em>Firmicutes</em> and increased <em>Bacteroidetes</em> levels. Significant differences in the abundance of pathogenic species were also observed after the participants completed the exercise interventions of either type.</p></div><div><h3>Conclusions</h3><p>Both types of exercise promoted subtle changes in the oral microbiota, confirming the modulatory effect of high-intensity interval training and moderate-intensity continuous training on the oral microbiome.</p><p>Clinical trial registration <span>NCT05220670</span><svg><path></path></svg>.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140346941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopause transition and cardiovascular disease risk","authors":"Erin R. Uddenberg ,&nbsp;Nancy Safwan ,&nbsp;Mariam Saadedine ,&nbsp;Maria D. Hurtado ,&nbsp;Stephanie S. Faubion ,&nbsp;Chrisandra L. Shufelt","doi":"10.1016/j.maturitas.2024.107974","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107974","url":null,"abstract":"<div><p>The risk of cardiovascular disease (CVD) notably increases in the fifth decade of a woman's life, coinciding with the onset of menopause and occurring 10 years later than the similar age-related increase in men. Menopause marks a significant transition in a woman's life and is accompanied by cardiometabolic changes, including a shift in body composition, increased blood pressure, disruptions in lipoproteins, and insulin resistance. There is increasing evidence that the menopause transition is a risk factor for CVD, independent of age-related changes, especially considering that the earlier the onset of menopause, the greater is the CVD risk. Further, menopause-related symptoms such as vasomotor symptoms, sleep disturbances, and mood changes may all have a direct impact on CVD risk. In this review, we summarize the current literature regarding CVD in midlife women, focusing on the cardiometabolic changes related to ovarian aging versus chronological aging, as well as those related to specific menopause characteristics, including age, type of menopause and the use of menopause hormone therapy.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140328653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Female-specific risk variables: From innocent bystanders to key players in cardiovascular risk prediction","authors":"Angela H.E.M. Maas","doi":"10.1016/j.maturitas.2024.107970","DOIUrl":"10.1016/j.maturitas.2024.107970","url":null,"abstract":"<div><p>There is an increasing interest among professionals in cardiovascular medicine in women-specific risk variables related to gynecologic conditions over the life span. Although adverse lifestyle factors, hypertension, dyslipidemia and insulin resistance are recognized as the most important risk factors in older women, there is still uncertainty over how to account for other risk variables. For instance, migraine from puberty onwards, chronic inflammatory conditions and mental stress affect cardiovascular risk in women. As prevention should start as early in life as possible, appropriate risk estimation in women at middle age is crucial. In case of doubt, a coronary artery calcium score with a computed tomography scan at a radiology department can be helpful to discriminate between low and high risk for an individual. This may also pave the way for safe menopausal hormone therapy if needed. In this paper we summarize the current status of women-specific and other relevant risk variables from the perspective of the cardiologist.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140283066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutrition of aging people with diabetes mellitus: Focus on sarcopenia","authors":"Almog Shalit ,&nbsp;Eleni Gerontiti ,&nbsp;Georgios Boutzios ,&nbsp;Eleni Korakianiti ,&nbsp;Fotini Kanouta ,&nbsp;Vasiliki Vasileiou ,&nbsp;Theodora Psaltopoulou ,&nbsp;Stavroula A. Paschou","doi":"10.1016/j.maturitas.2024.107975","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107975","url":null,"abstract":"<div><p>As populations age, chronic diseases accumulate, and new health conditions emerge. One noteworthy pair that warrants further evaluation is diabetes mellitus and sarcopenia, given that the latter occurs in 28 % of the population aged over 50 who have diabetes mellitus. The management of both entails nutritional interventions, making the development of unified dietary recommendations an alluring strategy. This review aims to elucidate the current recommendations for the combined management of sarcopenia and diabetes, while featuring elements that require further research. The goal of nutritional management is to improve muscle mass and strength while regulating metabolic risk and glucose levels. To ensure muscle synthesis in the elderly, recommendations align at daily calorie intake that exceeds 30 kcal/kg, with adjustments based on comorbidities. Additionally, a protein intake of at least 1–1.2 g/kg/d is essential, emphasizing both daily and per-meal intake, and can be achieved through diet or branched-amino-acids supplements. Specific considerations for diabetes include restricted protein intake in diabetic nephropathy and exploring the potential link between branched amino acids and insulin resistance. Further recommendations that both promote metabolic health and have demonstrated at least a potential to increase muscle strength include prioritizing polyunsaturated fatty acids as a fat source and maintaining adequate levels of vitamin D. Clinicians should consult their patients on dietary optimization, but evidence is insufficient to recommend additional supplementation. Lastly, an emerging challenge of diabetes and sarcopenia is sarcopenic obesity, which requires the combination of a hypocaloric diet with increased protein intake.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of an intrinsic capacity score in the UK Biobank study","authors":"Melkamu Bedimo Beyene ,&nbsp;Renuka Visvanathan ,&nbsp;Muktar Ahmed ,&nbsp;Beben Benyamin ,&nbsp;John R. Beard ,&nbsp;Azmeraw T. Amare","doi":"10.1016/j.maturitas.2024.107976","DOIUrl":"10.1016/j.maturitas.2024.107976","url":null,"abstract":"<div><h3>Background</h3><p>In 2015, the World Health Organization introduced the concept of intrinsic capacity (IC) to define the individual-level characteristics that enable an older person to be and do the things they value. This study developed an intrinsic capacity score for UK Biobank study participants and validated its use as a tool for health outcome prediction, understanding healthy aging trajectories, and genetic research.</p></div><div><h3>Methods</h3><p>Our analysis included data from 45,208 UK biobank participants who had a complete record of the ten variables included in the analysis. Factor adequacy was tested using Kaiser–Meyer–Olkin, Barthelt's, and the determinant of matrix tests, and the number of factors was determined by the parallel analysis method. Exploratory and confirmatory factor analyses were employed to determine the structure and dimensionality of indicators. Finally, the intrinsic capacity score was generated, and its construct and predictive validities as well as reliability were assessed.</p></div><div><h3>Results</h3><p>The factor analysis identified a multidimensional construct comprising one general factor (intrinsic capacity) and five specific factors (locomotor, vitality, cognitive, psychological, and sensory). The bifactor structure showed a better fit (comparative fit index = 0.995, Tucker Lewis index = 0.976, root mean square error of approximation = 0.025, root mean square residual = 0.009) than the conventional five-factor structure. The intrinsic capacity score generated using the bifactor confirmatory factor analysis has good construct validity, as demonstrated by an inverse association with age (lower intrinsic capacity in older age; (β) =−0.035 (95%CI: −0.036, −0.034)), frailty (lower intrinsic capacity score in prefrail participants, β = −0.104 (95%CI: (−0.114, −0.094)) and frail participants, β = −0.227 (95%CI: −0.267, −0.186) than robust participants), and comorbidity (a lower intrinsic capacity score associated with increased Charlson's comorbidity index, β =−0.019 (95%CI: −0.022, −0.015)). The intrinsic capacity score also predicted comorbidity (a one-unit increase in baseline intrinsic capacity score led to a lower Charlson's comorbidity index, β = 0.147 (95%CI: −0.173, −0.121)) and mortality (a one-unit increase in baseline intrinsic capacity score led to 25 % lower risk of death, odds ratio = 0.75(95%CI: 0.663, 0.848)).</p></div><div><h3>Conclusion</h3><p>The bifactor structure showed a better fit in all goodness of fit tests. The intrinsic capacity construct has strong structural, construct, and predictive validities and is a promising tool for monitoring aging trajectories.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224000719/pdfft?md5=547d829ce0e0f8de17b8ff9a1b040d23&pid=1-s2.0-S0378512224000719-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140202822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life is often compared to a marathon, so why do research and health promotion initiatives often treat it like a 100-m sprint?","authors":"","doi":"10.1016/j.maturitas.2024.107967","DOIUrl":"10.1016/j.maturitas.2024.107967","url":null,"abstract":"","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140202643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopically confirmed endometriosis and anti-Müllerian hormone levels: Findings from the Nurses' Health Study II","authors":"Leslie V. Farland ,&nbsp;Michelle Valenti ,&nbsp;William J. Degnan III ,&nbsp;Elizabeth R. Bertone-Johnson ,&nbsp;Holly R. Harris ,&nbsp;Amy D. DiVasta ,&nbsp;Kathryn M. Rexrode ,&nbsp;A. Heather Eliassen ,&nbsp;Stacey A. Missmer","doi":"10.1016/j.maturitas.2024.107969","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107969","url":null,"abstract":"<div><h3>Objective</h3><p>Anti-Müllerian hormone is a reliable measure of ovarian reserve associated with menopause timing and fertility. Previous studies have observed that individuals with endometriosis have lower anti-Müllerian hormone levels than those without. However, sample sizes have been small and information is limited regarding the long-term influence of endometriosis on anti-Müllerian hormone levels among the general population, which may have important implications for menopause timing and chronic disease risk.</p></div><div><h3>Methods</h3><p>Among 1961 premenopausal women in the Nurses' Health Study II who provided a blood sample and had not been pregnant in the last 6 months, we used generalized linear models to determine the association between laparoscopically-confirmed endometriosis and log-transformed plasma anti-Müllerian hormone level, adjusted for age (continuous and squared) and other potential confounding variables.</p></div><div><h3>Results</h3><p>Participants were on average 40 years old (interquartile range 37–42 years) at blood draw. Women with endometriosis diagnosed prior to blood draw (<em>n</em> = 119) had a lower mean anti-Müllerian hormone level (1.6 ng/mL [SD = 2.3]) than women without known endometriosis (<em>n</em> = 1842) (2.8 ng/mL [SD = 3.0]). In multivariable adjusted models, women with endometriosis had 29.6 % lower anti-Müllerian hormone levels (95 % CI: −45.4, −9.2 %) than women without. This association was greater among women with a body mass index of 25 kg/m² or more (percent difference: −44.0 % (−63.7, −13.8)), compared to those with a body mass index of under 25 kg/m² (percent difference: −19.8 % (−41.7, 10.4)), but did not vary by parity or infertility history.</p></div><div><h3>Conclusions</h3><p>Lower anti-Müllerian hormone levels in women with endometriosis may be one mechanism through which endometriosis influences risk of infertility, younger age at menopause, and cardiovascular disease.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140134216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthy ageing in a multi-ethnic population: A descriptive cross-sectional analysis from the HELIUS study","authors":"Marilyne Menassa ,&nbsp;Oscar H. Franco ,&nbsp;Henrike Galenkamp ,&nbsp;Eric P. Moll van Charante ,&nbsp;Bert-Jan H. van den Born ,&nbsp;Esther M.C. Vriend ,&nbsp;Pedro Marques Vidal ,&nbsp;Karien Stronks","doi":"10.1016/j.maturitas.2024.107972","DOIUrl":"https://doi.org/10.1016/j.maturitas.2024.107972","url":null,"abstract":"<div><h3>Objective</h3><p>We investigated ethnic health disparities in the Healthy Life in an Urban Setting multi-ethnic cohort using the multidimensional Healthy Ageing Score.</p></div><div><h3>Study design</h3><p>We conducted a cross-sectional analysis of the study baseline data (2011–2015) collected through questionnaires/physical examinations for 17,091 participants (54.8 % women, mean (SD) age = 44.5 (12.8) years) from South-Asian Surinamese (14.8 %), African Surinamese (20.5 %), Dutch (24.3 %), Moroccan (15.5 %), Turkish (14.9 %), and Ghanaian (10.1 %) origins, living in Amsterdam, the Netherlands.</p></div><div><h3>Main outcome measures</h3><p>We computed the Healthy Ageing Score developed in the Rotterdam Study, which has seven biopsychosocial domains: chronic diseases, mental health, cognitive function, physical function, pain, social support, and quality of life. That score was used to discern between healthy, moderate, and poor ageing. We explored differences in healthy ageing by ethnicity, sex, and age group using multinomial logistic regression.</p></div><div><h3>Results</h3><p>The Healthy Ageing Score [overall: poor (69.0 %), moderate (24.8 %), and healthy (6.2 %)] differed between ethnicities and was poorer in women and after midlife (cut-off 45 years) across ethnicities (all <em>p</em> &lt; 0.001). In the fully adjusted models in men and women, poor ageing (vs. healthy ageing) was highest in the South-Asian Surinamese [adjusted odds ratios (95 % confidence intervals)] [2.96 (2.24–3.90) and 6.88 (3.29–14.40), respectively] and Turkish [2.80 (2.11–3.73) and 7.10 (3.31–15.24), respectively] vs. Dutch, in the oldest [5.89 (3.62–9.60) and 13.17 (1.77–98.01), respectively] vs. youngest, and in the divorced [1.48 (1.10–2.01) and 2.83 (1.39–5.77), respectively] vs. married. Poor ageing was inversely associated with educational and occupational levels, mainly in men.</p></div><div><h3>Conclusions</h3><p>Compared with those of Dutch ethnic origin, ethnic minorities displayed less healthy ageing, which was more pronounced in women, before and after midlife, and was associated with sociodemographic factors.</p></div>","PeriodicalId":51120,"journal":{"name":"Maturitas","volume":null,"pages":null},"PeriodicalIF":4.9,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0378512224000677/pdfft?md5=27856a4aa18cab5961f58d6e2435c71e&pid=1-s2.0-S0378512224000677-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140162712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}